Dock and Lock: Novel Protein Engineering
对接和锁定:新型蛋白质工程
基本信息
- 批准号:7663212
- 负责人:
- 金额:$ 36.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-29 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:90YAcuteAffinityBehaviorBindingBispecific AntibodiesCEACAM5 geneCarcinoembryonic AntigenCell Culture TechniquesCicatrixClinicalClinical TrialsColorectalComplementarity Determining RegionsComplexDevelopmentDiagnosticDockingDrug KineticsFab ImmunoglobulinsFundingGlycineHaptensHistamineHumanImageImaging TechniquesLabetuzumabLeadLungMalignant - descriptorMethodsMusNon-MalignantOrangesPeptidesPhasePositioning AttributePositron-Emission TomographyProcessPropertyProtein EngineeringQualifyingRadiation therapyRadioimmunodetectionRadioisotopesRadiolabeledSafetySerumSiteSmall Business Innovation Research GrantStructureSystemTherapeuticTissuesToxic effectUpper armVertebral columnbasecancer imagingclinical applicationdesignhumanized antibodymalignant breast neoplasmmouse modelnovelpre-clinicalpreclinical studypublic health relevanceradiotracertumortumor xenograft
项目摘要
DESCRIPTION (provided by applicant): The objective of this Phase II application is the commercial development of CEA-ImmunoPET for breast cancer imaging. CEA-ImmunoPET is a two-component product system comprising TF2, a trivalent, bispecific, anti-CEA x anti-HSG constructs made by the Dock and Lock (DNL) method, and 68Ga-IMP288, a DOTA- derivatized di-HSG peptide radiolabeled with 68Ga. In the Phase I SBIR (1 R43 CA123985-01), we have achieved significant advancement towards clinical development of TF2 for radioimmunodetection and therapy of CEA-positive tumors with IMP288 radiolabeled with 111In or 124I. We have established the feasibility of clinical development of the TF2/IMP288 pretargeting system by (a) further optimizing the process of producing TF2 from cell cultures; (b) completing preclinical studies that have characterized the pharmacokinetic behavior of TF2 and IMP288 as well as obtaining the conditions that will lead to optimal pretargeting of tumors, (c) evaluating the tissue binding properties of TF2 and to some degree IMP288, and (d) initiating important acute toxicity studies that have shown the safety of both TF2 and IMP288. In this Phase II application, we will complete the preclinical development of TF2 and 68Ga-IMP288 to qualify its use for clinical trials, establish optimal pretargeting conditions in mouse models bearing human tumor xenografts that differ in the expression levels of CEA, and to submit an IND to the FDA. We plan to be in position to begin clinical trials for breast cancer imaging at the end of the Phase II funding period. PUBLIC HEALTH RELEVANCE: Pretargeting with CEA-ImmunoPET has the potential to become a breast cancer imaging technique that is convenient, non-invasive, non-scarring, highly sensitive and yet capable of clearly differentiating between malignant and non-malignant tissues.
描述(由申请人提供):本II期申请的目的是用于乳腺癌成像的CEA-ImmunoPET的商业开发。CEA-ImmunoPET是一种双组分产品系统,包含TF 2(通过Dock and Lock(DNL)方法制备的三价、双特异性抗CEA x抗HSG构建体)和68 Ga-IMP 288(用68 Ga放射性标记的DOTA衍生化二HSG肽)。在I期SBIR(1 R43 CA 123985 -01)中,我们在TF 2的临床开发方面取得了重大进展,用于放射免疫检测和用111 In或124 I放射性标记的IMP 288治疗CEA阳性肿瘤。我们已经通过以下步骤确定了TF 2/IMP 288预靶向系统临床开发的可行性:(a)进一步优化从细胞培养物生产TF 2的工艺;(B)完成表征TF 2和IMP 288的药代动力学行为的临床前研究,以及获得将导致肿瘤的最佳预靶向的条件,(c)评估TF 2和一定程度的IMP 288的组织结合特性,和(d)启动重要的急性毒性研究,这些研究已经显示TF 2和IMP 288的安全性。在这项II期申请中,我们将完成TF 2和68 Ga-IMP 288的临床前开发,以使其有资格用于临床试验,在携带CEA表达水平不同的人肿瘤异种移植物的小鼠模型中建立最佳预靶向条件,并向FDA提交IND。我们计划在第二阶段资助期结束时开始乳腺癌成像的临床试验。公共卫生相关性:CEA-ImmunoPET的预靶向有可能成为一种方便、无创、无瘢痕、高度敏感且能够清楚区分恶性和非恶性组织的乳腺癌成像技术。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex.
- DOI:10.1021/bc100137x
- 发表时间:2010-07-21
- 期刊:
- 影响因子:4.7
- 作者:McBride, William J.;D'Souza, Christopher A.;Sharkey, Robert M.;Karacay, Habibe;Rossi, Edmund A.;Chang, Chien-Hsing;Goldenberg, David M.
- 通讯作者:Goldenberg, David M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chien Hsing K. Chang其他文献
Chien Hsing K. Chang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chien Hsing K. Chang', 18)}}的其他基金
Use of milatuzumab in modulating graft vs. host disease
米拉妥珠单抗在调节移植物抗宿主病中的用途
- 批准号:
8061187 - 财政年份:2011
- 资助金额:
$ 36.68万 - 项目类别:
Novel RNase-based Immunotoxin for CD74-positive B-cell Malignancies
针对 CD74 阳性 B 细胞恶性肿瘤的新型基于 RNase 的免疫毒素
- 批准号:
7270883 - 财政年份:2007
- 资助金额:
$ 36.68万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 36.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 36.68万 - 项目类别:
Operating Grants